Coronavirus: Canadian vaccine yields promising early results

The University of Saskatchewan’s Vaccine and Infectious Disease Organization (VIDO) has announced positive early results from phase one trials of its COVID-19 vaccine candidate: COVAC-2. The results from the study show that the vaccine appears to be safe and “well tolerated,” according to a press release. The study, conducted by Canadian Centre for Vaccinology (CCfV), said that the most commonly reported side effects among those who received the vaccine were headaches and mild pain at the injection site.